Floatz logo

Dat-2645

BRCA Mutation

Danatlas Pharmaceuticals Co., LtdPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the BRCA Mutation cohort.

Asset / SponsorPhaseRating
Olaparib
Okayama University
Phase 3B
Cyclophosphamide
Okayama University
Phase 2CCC
TAMOXIFEN
European Institute of Oncology
Phase 2CCC
Pembrolizumab
Okayama University
Phase 2CCC
Tranexamic Acid
Northwestern University
Phase 2CCC

View all 12 →

Same molecule, other indications

Dat-2645 is also rated in:

ovarian cancerDormant
CCC
Indicative ·
53 / 100
View asset →
HRD CancerDormant
CC
Indicative ·
43 / 100
View asset →
Solid CancersDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →